Compare Marathon Petroleum Corp (MPC) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marathon Petroleum Corp vs Vertex Pharmaceuticals Incorporated — how do they compare? Marathon Petroleum Corp trades at $337.18 (market cap $89.95B), while Vertex Pharmaceuticals Incorporated trades at $529.5 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and Marathon Petroleum Corp pays a 1.25% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| MPC | VRTX | |
|---|---|---|
Market Cap | $89.95B | $132.79B |
Sector | Energy | Health |
52-Week High | $320.32 | $529.59 |
52-Week Low | $158.59 | $374.46 |
Enterprise Value | $116.48B | $126.92B |
Dividend Yield | 1.25% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marathon Petroleum (MPC) trades at $298.20, down 0.35% with a bearish technical signal despite strong fundamental performance. The stock shows exceptional earnings momentum with three consecutive quarterly beats, including a massive Q2 2026 EPS of $17.73 versus $14.27 expected. Valuation remains attractive with P/E of 10.34 and EV/EBITDA of 6.26, while maintaining robust profitability with 47.9% ROE.
MPC presents a compelling investment case with strong analyst support (76% buy ratings) and $330.70 price target upside. However, declining revenue trends from $177.5B in 2022 to $132.7B in 2025 and rising debt-to-asset ratio to 42.59% pose fundamental concerns. Technical weakness near pivot point resistance at $297 requires monitoring despite positive refining margin outlook.
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
